Abstract: Described herein is a beverage system that is configured to produce beverages having different characteristics, such as different levels of carbonation including producing substantially non-carbonated beverages and carbonated beverages with a single machine. The beverage system includes a beverage appliance and a beverage container. The beverage container includes a beverage material, which can include a flavoring ingredient for a target beverage. The beverage appliance is used to access the beverage material from the beverage container and produce the target beverage. The beverage appliance and beverage container are adaptable to produce the target beverage having any of a range of carbonation levels or other characteristics.

Abstract: The use in preparation of a medicament for treating and preventing the side effects of anti-cancer chemotherapy of a polyunsaturated fatty acid with a carbon chain length of 14 to 26 and with 2 to 6 double bonds in the molecule in cis or trans configuration, and a method of such treatment or prevention wherein said fatty acid is used as an active.

Abstract: The use in preparation of a medicament for treating and preventing the side effects of anti-cancer chemotherapy of a polyunsaturated fatty acid with a carbon chain length of 14 to 26 and with 2 to 6 double bonds in the molecule in cis or trans configuration, and a method of such treatment or prevention wherein said fatty acid is used as an active.

Abstract: An aqueous tannin stain-inhibiting coating composition comprising a titanate coupling agent. Also, a process for inhibiting tannin staining in a tannin-containing substrate is disclosed which involves applying to the substrate a coating composition comprising a titanate coupling agent.

Abstract: Damage to the gastrointestinal tract as a consequence of exposure to ionising radiation is prevented or treated by administration of GLA and/or DGLA. Medicaments containing GLA and/or DGLA for such treatment or prevention may also further comprise EPA and/or DHA.

Abstract: Damage to internal tissues, and particularly to the central nervous system as a consequence of exposure to ionizing radiation is prevented or treated by administration of GLA and/or DGLA. Medicaments containing GLA and/or DGLA for such treatment or prevention may also further comprise EPA and/or DHA.

Abstract: Method of safe intravenous administration of fatty acid(s), and in particular the n-6 and n-3 series essential fatty acids and conjugated fatty acids, whereby the fatty acid(s) or a proportion thereof are administered in the form of lithium salts, and whereby the plasma lithium levels are regularly monitored to avoid haemolysis, preferably keeping the lithium level no higher than 0.7 millimolar in the long term and preferably also no higher than 0.4-0.5 millimolar in the first 24-48 hours or, where only a proportion of the fatty acids are administered as lithium salts, a corresponding proportion of said levels.